BC
BPMC

Brookfield Corp’s Blueprint Medicines BPMC Stock Holding History

Brookfield Corp’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-61,165
Closed -$4.03M – 596
2022
Q3 		$4.03M Sell
61,165
-12,168
-17% -$782K 0.01% 304
2022
Q2 		$3.7M Buy
+73,333
New +$4.3M 0.02% 309
2022
Q1 		– Sell
-11,414
Closed -$1.22M – 634
2021
Q4 		$1.22M Buy
+11,414
New +$1.19M ﹤0.01% 407

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Brookfield Corp's BPMC Position: Q4 2022 in Review

Brookfield Corp sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 61,165 shares — an estimated $4.03M sold.

Brookfield Corp first reported a position in BPMC in Q4 2021 and held it in 3 quarters. The position peaked at $4.03M in Q3 2022. 222 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

  • Brookfield Corp reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
  • Brookfield Corp sold 61,165 Blueprint Medicines shares in Q4 2022, an estimated $4.03M.
  • Brookfield Corp first reported a position in Blueprint Medicines in Q4 2021 and held it in 3 quarters.
  • Brookfield Corp's Blueprint Medicines position peaked at $4.03M in Q3 2022.
  • 222 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on Brookfield Corp's 13F filing for Q4 2022, filed 14 Feb 2023.